
    
      This is a Phase 3, multi-center, open-label long-term extension study in Japanese NDO
      subjects who participated and completed in the precedent Study A0221047 which is a 24 weeks,
      randomized, open label study, to investigate the safety and tolerability of fesoterodine.

      This study consists of a 28-week open-label treatment period followed by a 4-week follow-up.
      In addition, subjects in the oxybutynin arm of the precedent Study A0221047 will continue the
      fesoterodine treatment until Week 40 visit in this study, in order to obtain fesoterodine 1
      year treatment data.
    
  